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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARY proliferating neural progenitors become committed to theThe proneural transcription factor Ascl1 coordinates
gene expression in both proliferating and differenti-
ating progenitors along the neuronal lineage. Here,
we used a cellular model of neurogenesis to investi-
gate how Ascl1 interacts with the chromatin land-
scape to regulate gene expression when promoting
neuronal differentiation. We find that Ascl1 binding
occurs mostly at distal enhancers and is associated
with activation of gene transcription. Surprisingly,
the accessibility of Ascl1 to its binding sites in neural
stem/progenitor cells remains largely unchanged
throughout their differentiation, as Ascl1 targets
regions of both readily accessible and closed chro-
matin in proliferating cells. Moreover, binding of
Ascl1 often precedes an increase in chromatin
accessibility and the appearance of new regions of
open chromatin, associated with de novo gene
expression during differentiation. Our results reveal
a function of Ascl1 in promoting chromatin accessi-
bility during neurogenesis, linking the chromatin
landscape at Ascl1 target regions with the temporal
progression of its transcriptional program.
INTRODUCTION
The generation of neurons in the developing central nervous sys-
tem requires a number of precisely orchestrated steps, whereby1544 Cell Reports 10, 1544–1556, March 10, 2015 ª2015 The Authorneuronal fate, exit cell cycle, and undergo a long and complex
program of migration and differentiation (Kriegstein and
Alvarez-Buylla, 2009). Proneural transcription factors (TFs) of
the bHLH family, such as Ascl1/Mash1, are the main regulators
of neurogenesis in the mammalian brain, and gain and loss-of-
function analyses have shown that they are both required and
sufficient to promote neurogenesis (Bertrand et al., 2002; Wilkin-
son et al., 2013). Accordingly, while genetic ablation of proneural
genes in mice results in neural developmental defects associ-
ated with reduced neurogenesis, overexpression of proneural
factors in neural progenitors induces a full neuronal differentia-
tion program (Berninger et al., 2007b; Casarosa et al., 1999;
Geoffroy et al., 2009). In addition to its pivotal role in develop-
ment, Ascl1 has been extensively used in protocols to reprogram
somatic cells, including fibroblasts, astrocytes, and pericytes,
into induced neurons (Berninger et al., 2007a; Karow et al.,
2012; Vierbuchen et al., 2010), renewing interest in understand-
ing the neurogenic activity of this proneural factor.
Previously, we characterized the transcriptional program of
Ascl1 in the ventral telencephalic region of the embryonic mouse
brain by combining gene expression profiling with chromatin
immunoprecipitation (ChIP), followed by hybridization to pro-
moter oligonucleotide arrays (ChIP-chip). This work resulted in
the identification of a set of Ascl1 target genes with various bio-
logical roles at distinct stages of the differentiation program,
raising intriguing questions concerning the molecular basis for
such temporal pattern (Castro et al., 2011; Vasconcelos and
Castro, 2014). In addition, it led to the identification of a
novel function for Ascl1 in maintaining cell proliferation, medi-
ated by the direct activation of genes that promote cell cycles
progression. This resulted in amodel whereby this proneural fac-
tor sequentially promotes the proliferation and differentiation of
progenitor cells along the neuronal lineage, reconciling the clas-
sical view of this proneural protein as a differentiation factor with
the fact that it is mostly expressed in cycling progenitors. More-
over, a recent study has shown that these two opposing activ-
ities are associated with distinct modes of Ascl1 expression,
with oscillating or sustained Ascl1 promoting proliferation or
differentiation, respectively (Imayoshi et al., 2013).
In spite of the significant progress made on the characteriza-
tion of its transcriptional targets, little is still known about how
Ascl1 regulates gene expression. In particular, the relationship
between Ascl1 binding, regulation of the chromatin landscape,
and gene transcription is poorly understood. It was recently
shown that during neuronal reprogramming, Ascl1 can access
its cognate sites in nucleosomal-DNA when ectopically ex-
pressed in fibroblasts, defining it as a pioneer TF (Wapinski
et al., 2013). However, it remains to be seenwhether Ascl1 works
as a pioneer factor in a neurogenic context and whether binding
of Ascl1 results in alterations to the chromatin landscape at its
target regions, as it has been shown for some, but not all, other
pioneer TFs (Zaret and Carroll, 2011).
Mammalian neurogenesis is not a synchronized process at a
cell population level and studies to investigate the mechanistic
basis of Ascl1 function at a genome-wide scale are difficult to
perform in the developing embryo or in the adult brain. An alter-
native is the use of adherent cultures of neural stem (NS) cell lines
derived from embryonic stem cells or embryonic neural precur-
sors (Conti et al., 2005; Pollard et al., 2006). These cultures pro-
vide us with reliable models to study neurogenesis in culture,
without the confounding effects of cellular heterogeneity, char-
acteristic of other cellular models such as neurospheres. In
proliferating culture conditions, endogenous Ascl1 regulates a
progenitor program that functions to maintain cell proliferation
(Castro et al., 2011), whereas overexpression of Ascl1 leads to
efficient cell cycle exit and neuronal differentiation.
Here we investigate how Ascl1 activity is restricted by and im-
pacts the chromatin landscape, when driving neuronal differen-
tiation. We combined expression profiling with genome-wide
mapping of Ascl1 binding sites (ChIP-seq) (Park, 2009), and
DNase I hypersensitivity sites (DNase-seq) (Song and Crawford,
2010), in a cellular model of neurogenesis driven by overex-
pressed Ascl1. We identify a large number of genes directly
regulated by Ascl1 and characterize widespread changes in
chromatin accessibility during differentiation. Ascl1 binding cor-
relates with activation of gene transcription, targeting not only re-
gions of accessible but also of closed chromatin. In addition,
binding of Ascl1 to DNA precedes a local increase in chromatin
accessibility at the regulatory regions of its target genes,
providing the first direct link between Ascl1 regulation of gene
expression and local changes in chromatin landscape.
RESULTS
A Cellular Model of Ascl1-Driven Neurogenesis
Overexpression of Ascl1 promotes cell cycle exit and neuronal
differentiation of neural progenitor cells (Castro et al., 2006). To
study this process in controlled conditions, we established aCellcellular model of Ascl1-driven neurogenesis by expressing an
inducible version of Ascl1 in NS cells in culture (NS5 cell line)
(Pollard et al., 2006). Fusion of full-length Ascl1 to the modified
ligand binding domain of the estrogen receptor (ERT2) renders
Ascl1 activity dependent on the presence of 4-hydroxytamoxifen
(herein referred to as tamoxifen) (Bergstrom et al., 2002; Burk
and Klempnauer, 1991; Littlewood et al., 1995). In a transcrip-
tional assay in transfected NS cells, Ascl1-ERT2 induces the
transcriptional activation of an enhancer of the Ascl1 target
gene Dll1 (Castro et al., 2006) in an inducible manner to levels
that are similar to its WT counterpart (Figure S1A). In order to
test for the ability of the inducible Ascl1 protein to promote
neuronal differentiation, we transduced NS cells in culture with
a retrovirus vector co-expressing Ascl1-ERT2 and green fluores-
cent protein (GFP). In the vast majority of transduced cells,
drastic morphological changes characterized by the extension
of long processes and associated with the expression of the
neuronal marker Tuj1 were observed only upon the addition of
tamoxifen, confirming the ability of Ascl1-ERT2 to activate the
neurogenic differentiation program in an inducible manner
(Figure S1B). Although activation is associated with the nuclear
translocation of a small fraction of Ascl1-ERT2, most of the pro-
tein is already nuclear prior to addition of tamoxifen (as previ-
ously reported with other cases of TFs fused to ERT2) (Burk
and Klempnauer, 1991; Roemer and Friedmann, 1993), and
additional mechanisms must therefore contribute to the induc-
ibility of Ascl1-ERT2 (Figure 1A).
To obtain large numbers of synchronized differentiating neural
progenitors, we used antibiotic selection following the retroviral
delivery of the Ascl1-ERT2 transgene. Quantification of immuno-
fluorescence levels upon immunohistochemistry estimated the
total Ascl1 protein level in transduced cells to be 8- to 9-fold
higher when compared with endogenous Ascl1 expressed in
embryonic ventral telencephalic progenitors (Figure 1B). NS cells
expressing Ascl1-ERT2 plated at low density differentiate with
great efficiency upon addition of tamoxifen (Figure 1C). Four
days after induction, immunocytochemical analysis shows
expression of the rate limiting enzyme for GABA synthesis gluta-
mic acid decarboxylase GAD65/67 (15.1% ± 0.3%) (Figure 1D).
Whole-cell patch-clamp recordings of retrovirus-transduced
cells 14 days after onset of tamoxifen treatment show that these
cells consistently exhibit electrophysiological properties of
neurons (Figure 1E). Moreover, their action potential discharges
pattern in response to step current injections is highly reminis-
cent of low-threshold burst spiking interneurons and very similar
to those generated frommedial ganglionic eminence progenitors
of the ventral telencephalon (Figure 1D) (Martı´nez-Cerden˜o et al.,
2010). To characterize the transcriptome changes in our model,
we performed expression profiling at various time points 4, 12,
24, and 50 hr after the onset of differentiation. A large number of
genes (1,508) are differentially regulated at least at one time point
(fold change >1.5, p < 103; see Figure 1F for a breakdown
of numbers), as expected upon induction of a cellular differenti-
ation program (Table S1). Functional annotation of differentially
expressed genes by Gene Ontology shows considerable enrich-
ment in terms associated with distinct phases of neurogenesis,
describing both early events (e.g., ‘‘Notch signaling,’’ ‘‘cell divi-
sion’’) and later steps of the differentiation program (e.g., ‘‘cellReports 10, 1544–1556, March 10, 2015 ª2015 The Authors 1545
Figure 1. A Cellular Model of Neurogenesis Driven by Ascl1
(A) Cellular localization of Ascl1-ERT2 in NS5 cells before and 30 min after the addition of tamoxifen, as assessed by immunostaining against HA-tag (green).
White arrowheads mark cytoplasmic expression in the absence of tamoxifen. Cell nuclei are labeled with DAPI (blue). Scale bar represents 30 mm.
(B) Quantification of total Ascl1 protein levels in E14.4 ventral telencephalic progenitors (left) or NS5 Ascl1-ERT2 cells (right). Histograms show absolute fluo-
rescence intensity after normalization (see Experimental Procedures for details).
(C) State of differentiation of NS5Ascl1-ERT2 cells in the presence or absence of tamoxifen 3 days after induction of differentiation, as assessed by the expression
of the neuronal marker TUJ1 (red). Cell nuclei are labeled with DAPI (blue). Scale bar represents 200 mm.
(D) Expression of Gad65/67 (red) in NS5 Ascl1-ERT2 cells 4 days after induction of differentiation. Cell nuclei are labeled with DAPI (blue). Scale bar represents
200 mm.
(E) Electrophysiological properties of GFP-labeled neurons generated from NS5 Ascl1-ERT2 cells 14 days upon induction of differentiation. Representative
responses of two neurons to step-current injection at a holding potential of 70mV in current-clamp mode. Note the brief burst of action potentials on top of a
prolonged calcium spike following depolarization (red traces) and the rebound burst following release from hyperpolarization (black trace). Scale bar represents
200 mm.
(legend continued on next page)
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Figure 2. Genome-wide Mapping of Ascl1
Binding Sites in Differentiating NS Cells
(A) Location of Ascl1 BEs respective to various
genomic features.
(B) Location of Ascl1 BEs in relation to the closest
annotated TSS.
(C) Chromatin state in differentiating NS cells, at
Ascl1 bound regions in the vicinity of Fbxw7,Olig2,
and Dll3 genes.
(D) Heat maps of chromatin states for H3K27ac
and H3K4me1 within ±2 kb of Ascl1-ERT2 peak
summits in proliferating or differentiating NS cells
(before and 24 hr after the addition of tamoxifen,
respectively).
(E) DNA motif enrichment for Ascl1 E-box within a
20-bp region centered at Ascl1 peak summits (R,
enrichment over local genomic background; S,
motif score).
See also Figure S2.migration,’’ ‘‘axon guidance’’) (Figure 1G). Overall, these results
show Ascl1 drives an extended program of neuronal differentia-
tion in our model.
Genome-wide Location Analysis of Ascl1 in
Differentiating NS Cells
To understand how the observed changes in gene expression
relate to Ascl1 function, we mapped Ascl1 binding sites(F) Experiment design for the transcriptome analysis and the resulting number of deregulated genes determ
ferentiation (fold change > 1.2, p < 103).
(G) Enrichment of Gene Ontology biological process terms among genes deregulated during neuronal differen
term is in brackets.
See also Figure S1.
Cell Reports 10, 1544–1556genome-wide by ChIP followed by
massive parallel sequencing (ChIP-seq)
(Wapinski et al., 2013), using an antibody
against the HA tag of Ascl1-ERT2. This
was performed 18 hr after the onset of
differentiation, at a time point when NS
cells have already undergone large tran-
scriptional changes. Using input chro-
matin as control, we defined an extended
list comprising 21,582 Ascl1 binding
sites, with FDR <0.5% and p < 1010
(Table S2).
In order to validate binding events
(BEs) mediated by the Ascl1-ERT2
protein, we used ChIP-PCR against WT
Ascl1, with chromatin extracted from
embryonic E14.5 ventral telencephalic
progenitors, orWTNS5 cells (Figure S2A).
We reasoned that most BEs in differen-
tiating NS cells should be identified in at
least one of the chromatin samples.
Indeed, this is the case for all ChIP-seq
peaks associated with p < 1018 (with
themajority of BEs validated in both chro-matins), indicating a good match between Ascl1-ERT2 and WT
Ascl1. Most of the 11,782 Ascl1 BEs defined by this high-confi-
dence list (p < 1018) are located within intergenic regions (63%)
and at long distances from the nearest identified transcription
start site (TSS). Less than one third of Ascl1 binding occurs in-
side genes (30%) or their promoter regions (7%) (Figures 2A
and 2B), suggesting that Ascl1 binds predominantly to distal
enhancer regions. We next used a Hidden-Markov model toined at different time points after induction of dif-
tiation. Total number of genes associatedwith each
, March 10, 2015 ª2015 The Authors 1547
Figure 3. Ascl1 Functions as a Transcrip-
tional Activator at a Genome-wide Level
(A) Cumulative fraction of Ascl1 BEs considered
regulatory by association with upregulated or
downregulated genes following a nearest gene
annotation. The dashed line marks the most
stringent cutoff (p < 1025) for peak enrichment
and defines a list of BEswith the highest regulatory
potential (n = 8,624, 2.5 times over control).
(B) Heat map displaying the cumulative fraction of
deregulated genes 12 hr after induction of differ-
entiation that is directly regulated by Ascl1 (up, top
left panel; down, bottom left panel). Transcripts
are divided in equal bins of decreasing expression
fold change and plotted against Ascl1 BEs (bin =
166) with increasing p value. Control: 100 sets of
random BEs (right, mean value shown).
(C) Heat maps displaying the cumulative fraction
of upregulated genes at 4, 12, 24, and 50 hr after
induction of differentiation, defined as in (B).
(D) Association of Ascl1 BEs to each gene cluster.
The red (activation) or blue (repression) bar rep-
resents the number of high-confidence Ascl1 BEs
(p < 1025) annotated to genes belonging to each
cluster and is juxtaposed to the distribution of
Ascl1 binding annotations, which can be found in
1,000 different random clusters of genes. Test
data represented as box with median of test and
first and third quartiles; whiskers, ±1.5 3 in-
nerquartile range (IQR).
See also Figures S3–S5.characterize the chromatin states at Ascl1-bound regions,
using genome-wide profiles of histone modifications generated
from proliferating and differentiating NS cells (before or 24 hr
after addition of tamoxifen, respectively) (Ernst and Kellis,
2012). Ascl1 BEs fall mostly within regions of chromatin highly
co-enriched for H3K4me1 and H3K27ac, characteristic of
active enhancers (same result for p < 1010; data not shown).
Moreover, the same association with this chromatin state is
found in proliferating NS cells, indicating that during differen-
tiation Ascl1 binds predominantly to regions that are already
marked as active enhancers in proliferating NS cells (Figures
2C, 2D, and S2B).
To determine the DNA sequence mediating Ascl1 binding, we
searched for motifs enriched within the 20 nucleotides region
centered under the Ascl1 peak summits. A strong preference is
found for the hexamer sequence CAGCTG, corresponding to
the E-box type sequence previously associated with Ascl1 bind-1548 Cell Reports 10, 1544–1556, March 10, 2015 ª2015 The Authorsing (Castro et al., 2011) and in agreement
with its role in mediating direct DNA bind-
ing (Figure 2E).
Ascl1 Functions Globally as a
Transcriptional Activator
Although it is generally believed that
proneural factors function by activating
gene transcription, some reports have
challenged this view (Alvarez-Rodrı´guez
and Pons, 2009; Rheinbay et al., 2013).In order to investigate this issue, we started by performing an
in depth cross-comparison between the location analysis and
expression profiling results, annotating each Ascl1 BE to its
nearest TSS. Direct comparison with the set of deregulated
genes previously described shows that only a small fraction
of BEs are considered to be regulatory using nearest gene
annotation (Figure 3A). Nonetheless, we find a positive correla-
tion between peak height (which is proportional to significance
of binding, or p value) and its potential to upregulate gene
expression (top peaks 20%). In contrast, the fraction of regu-
latory peaks that can be associated to repressed genes is
invariant with changes in peak size, suggesting no direct rela-
tion between Ascl1 binding significance and downregulation
of gene expression. Therefore, mere binding of Ascl1 to chro-
matin does not predict a regulatory event; however, the size
of an Ascl1 peak may be correlated with its potential to activate
gene transcription.
To have a global view of the association between the data
sets of genes bound by Ascl1 and regulated during differentia-
tion, we determined the frequency at which deregulated genes
(grouped in bins of increasing thresholds of fold change of
expression) are associated with Ascl1 BEs (grouped in bins of
increasing p value cutoff) and therefore considered to be directly
regulated by Ascl1 (Figure 3B, left). The statistical significance
of the overlaps was assessed by a similar comparison against
100 randomly generated control ChIP-seq data sets of identical
size (Figure 3B, right). The resulting heat maps indicate a strong
association between Ascl1-bound genes and those upregulated
during differentiation and a much less pronounced association
with downregulated genes (Figure 3B, top left versus bottom
left). Moreover, the fraction of downregulated genes that
are considered Ascl1 targets is very similar to that expected
by chance (Figure 3B, left versus right). Altogether, the above
analysis indicates that Ascl1 functions globally as a transcrip-
tional activator. In addition, this function is independent of
the progress of differentiation during the first 50 hr, as shown
with similar analyses for the different time points considered in
the transcription profiling (Figures 3C and S3). Importantly,
restricting the analysis to the Ascl1 BEs located within ±5 kb
of a TSS, producing a more stringent gene annotation, results
in a similar conclusion (Figure S4).
To integrate the transcriptional profiling data sets collected at
distinct time points, we applied a fuzzy c-means clustering algo-
rithm, resulting in the identification of seven distinct temporal
clusters (clusters 1–4 comprised of upregulated genes, clusters
5–7 of downregulated genes) (Figure S5; Table S3). Clusters of
genes that are upregulated during differentiation are all strongly
associated with Ascl1 BEs (p% 1.33 1011, 8.03 10126, 1.13
1022, and 7.9 3 1010 for clusters 1, 2, 3, and 4, respectively),
whereas clusters of downregulated genes show no such associ-
ation (Figure 3D), further indicating that Ascl1 binding correlates
with transcriptional activation.
Characterization of Ascl1 Transcriptional Program
The relative size of each cluster (Figure S5B) and their
enrichment for BEs indicate that most Ascl1 target genes fall
within a cluster characterized by an early activation profile
(cluster 2), while a smaller but significant number is upregulated
at mid or late time points (clusters 3 and 4, respectively). We
then compiled a high-confidence list of 272 Ascl1 direct targets
comprising genes from clusters 2, 3, and 4 that are associated
with at least one Ascl1 BE with high regulatory potential
(p < 1025) (Table S4). A search for terms describing ‘‘Biological
Process,’’ ‘‘Molecular Function,’’ and ‘‘Pathways’’ (Panther
Classification System) revealed the segregation in each tempo-
ral cluster of Ascl1 target genes encoding proteins of distinct
classes and functions, suggesting the control of various sub-
programs at distinct developmental stages (Figure S5C). Genes
with the earliest onset of activation (belonging to cluster 2) are
associated with signal transduction and cell communication,
while targets with a mid-onset of activation (cluster 3) encode
mostly proteins with a function related to transcription or
Notch signaling. Genes with latest onset (cluster 4) are enriched
for generic terms associated with neural development and
relate to late events in the differentiation program, from cellCellmigration to axonal growth and guidance (Figure S5C). In
summary and in agreement with our previous study performed
on a smaller scale, the identification of Ascl1 target genes in
our neurogenesis model demonstrates the direct control of
distinct components of the neurogenic differentiation program
by Ascl1.
Ascl1 Access to Its Target Sites Does Not Depend on the
Differentiation Stage of NS Cells
It was previously shown that Ascl1 target genes display
different onsets of expression at distinct stages of the neuronal
lineage (Borromeo et al., 2014; Castro et al., 2011). Such
temporal patterning could be associated with distinct accessi-
bilities of Ascl1 to its binding sites (e.g., due to differences in
the chromatin landscape). To investigate this, we compared
the binding profile of overexpressed Ascl1 at two distinct
stages by extending the previous ChIP-seq analysis to a time
point at the onset of differentiation (30 min upon addition of
tamoxifen) (Table S9). Surprisingly, visual inspection of the
genomic distribution of Ascl1 peaks finds a remarkable similar-
ity between Ascl1 BEs at t = 30 min and t = 18 hr (Figure 4A).
Comparison of the two Ascl1 binding profiles in a bin-by-bin
approach within the confidence limits defined by the previous
ChIP-PCR validation (Figure 4B, dashed line) shows an overlap
of 86% between the two stages (Figure 4B). Furthermore,
the presence of normalized sequencing signal across both
samples in genomic regions centered at putative sample-spe-
cific BEs suggests that the overlap of occupancies may have
been underestimated by peak calling conditions (Figure 4C).
Overall, our results indicate that the accessibility of Ascl1 to
the full complement of its binding sites remains largely identical
throughout differentiation.
Characterization of Chromatin Landscape Changes
during Differentiation
We next asked what impact Ascl1 may have on the chromatin
landscape when it promotes neuronal differentiation of NS cells.
We started by characterizing the chromatin landscape of prolif-
erating NS cells and of NS cells undergoing differentiation by
Ascl1, using aDNase I hypersensitivity assay coupled tomassive
parallel sequencing (DNase-seq). This technique identifies re-
gions of decreased nucleosome occupancy (herein referred as
‘‘open chromatin’’) on a genome-wide scale, which correspond
mostly to active regulatory elements such as promoters, en-
hancers, insulators, and silencers (Boyle et al., 2008; Natarajan
et al., 2012; Thurman et al., 2012). The density of mapped reads
for each genome position was computed to generate a compre-
hensive list of DNase I hypersensitivity sites (DHSs). Using a con-
stant threshold of p < 105, we identified 87,000 and 94,000
DHSs in proliferating and differentiating NS cells, respectively
(Tables S5 and S6), numbers with a magnitude consistent with
those obtained in other cell types (Song et al., 2011). Although
the majority of these sites is shared by both experimental condi-
tions, each cell state exhibits a specific set of 20,000 DHSs
(Figure 5A).
Since Ascl1 functions as a transcriptional activator, we
focused on the DHSs induced during differentiation (Table S7),
as these are more likely to provide new insights into Ascl1Reports 10, 1544–1556, March 10, 2015 ª2015 The Authors 1549
Figure 4. Ascl1 Accessibility to Its Target
Sites Remains Similar throughout Differen-
tiation
(A) Visual representation of ChIP-seq profiles at
t = 30 min (blue) and t = 18 hr (red) in a large
genomic region centered on Dll3 gene.
(B) Comparison of Ascl1 BEs at t = 30 min and
t = 18 hr (p < 1010) by cumulative bins of
increasing p value (bin = 1,007). The proportion of
sites bound by Ascl1 in both conditions (over-
lapping peaks) is calculated in relation to the
condition with the lowest number of BEs. Dashed
lines represent higher confidence lists defined by
p < 1018, analyzed in (C).
(C) Density plot of Ascl1 ChIP-seq reads mapping
to the genomic regions surrounding the summit of
Ascl1 BEs. The signal intensity represents the
Ascl1 ChIP-seq normalized tag count in the 4kb
region surrounding the summit of each over-
lapping (top) and nonoverlapping peak at
t = 30 min (blue) and t = 18 hr (red).function. To validate these DHSs, we used formaldehyde-assis-
ted isolation of regulatory elements (FAIRE), an alternative
method to identify regions of open chromatin. Although distinct
preferences have been described for each technique in
the identification of distal or proximal regulatory regions, the
two techniques have been shown to yield largely overlapping
results on a genome-wide basis (Song et al., 2011). Indeed,
9 of 13 tested regions presented more than 2-fold enrichment
by FAIRE-PCR across samples collected before and 24 hr
after addition of tamoxifen, as opposed to control regions
(Figure 5B).
Induced DHSs Are Associated with Genes Expressed De
Novo during Differentiation
Next, we investigated how regions of chromatin newly opened
during differentiation may be associated with the observed
changes in gene expression. We find a statistically significant
enrichment of differentiation-induced DHSs in the vicinity of up-
regulated genes (the sum of clusters 1–4; p < 1.3 3 1029), in
sharp contrast with downregulated genes (clusters 5–7) (Fig-
ure 5C). Moreover, a large fraction of all upregulated genes
(413 of 760) is associated with at least one differentiation-1550 Cell Reports 10, 1544–1556, March 10, 2015 ª2015 The Authorsinduced DHS, suggesting the importance
of these putative regulatory regions in
activating gene expression during neuro-
genesis. Notably, upregulated genes
associated with differentiation-induced
DHSs are either not expressed in prolifer-
ating NS cells or expressed at a low level
when compared with upregulated genes
near constant DHSs (Figure 5D). This
is well exemplified by the induction of
NeuroD4, a pro-differentiation TF only
expressed in post-mitotic precursors
(Ohsawa et al., 2005), and which is asso-
ciated with newly open DHSs (Figure 6B).Overall, our results indicate that activation of differentiation
genes is strongly associated with the appearance of new DHSs.
Ascl1 Promotes Chromatin Accessibility
In order to investigate which DNA-binding TFs may be associ-
ated with the appearance of newly open chromatin regions,
we took advantage of the high resolution potential of Digital
Genomic Footprinting (DGF) applied to DNase-seq data to
determine the position of sites occupied by TFs within differenti-
ation-induced DHSs (Figure 5E) (Piper et al., 2013). DGF identi-
fied almost 17,000 genomic sites (Table S8) with significant
occupancy levels (p < 1010), and the corresponding sequences
were then subject to a search for frequency of motif occurrence.
The most abundant motif found corresponds to the consensus
sequence of CTCF and is likely to reflect its frequent binding to
insulator regions identified by DNase-seq (Figure 5E) (Thurman
et al., 2012). Three additional motifs reveal binding by TFs of
the bHLH or NFI families, with the most frequent one corre-
sponding to the E-box consensus sequence, which mediates
Ascl1 binding. This observation establishes Ascl1 as a prime
candidate to promote the opening of chromatin structure and
induce new DHSs during differentiation.
Figure 5. Characterization of Changes in
Chromatin Accessibility during Differentia-
tion of NS Cells
(A) Number of DHSs in proliferating NS cells and
24 hr upon Ascl1-mediated differentiation.
(B) FAIRE-PCR validation of differentiation-
induced DHSs. Bars show fold enrichment of
genomic DNA obtained from NS cells 24 hr after
induction over cells prior to addition of tamoxifen.
Data are represented as mean ± SD.
(C) Differentiation-induced DHSs are significantly
associated with clusters of activated genes (left)
and not with clusters of repressed genes (right).
Red bars, total number of DHSs annotated to each
set of genes; boxplots, distribution of DHSs as-
sociations with 1,000 random sets of genes. Test
data are represented as box with median of test
and first and third quartiles; whiskers, ±1.53 IQR.
(D) Activated genes associated with differentia-
tion-induced DHSs have low or no expression in
proliferating cells. Gene expression levels in
proliferating cells are significantly lower (p < 1011,
Wilcoxon test) for activated genes associated with
induced DHSs (right) than for activated genes with
no such association (left). Red bar, level of
expression of NeuroD4 gene. Data distribution
represented as box with median and first and third
quartiles; whiskers, ±1.5 3 IQR; notches, ±1.58 3
IQR/n1/2).
(E) Frequency of motif occurrence at high occu-
pancy sites found within differentiation-induced
DHSs by Digital Genomic Footprinting (over-
representation ratio indicated between brackets).
(F) Comparison of Ascl1 BEs at t = 30 min (left) or
t = 18 hr (right) with the DNase-seq profile. Color
shows the proportion of Ascl1 BEs by cumulative
bins of increasing p value (bin = 1,842), which fall
within regions of open chromatin (DHSs) in prolif-
erating (top) or differentiating (bottom) NS cells.To understand how Ascl1 binding may relate to the observed
changes in chromatin compaction, we compared the genomic
distribution of Ascl1 BEs with that of DHSs before and after
neuronal differentiation (Figure 5F). Ascl1 ChIP-seq and DNase-
seq data sets show a high degree of overlap (e.g., 80.3% of
Ascl1 BEs with p < 1018 at t = 30 min fall within DHSs in prolifer-
ating cells), indicating that a large fraction of BEs, but not all,
occur in regions of open chromatin in proliferating NS cells (Fig-
ure 5F). Strikingly, this overlap increases significantly under dif-
ferentiation conditions (to 91.05% after differentiation, in theCell Reports 10, 1544–1556aforementioned case; Figure 5F). Alto-
gether, a comparison between the Ascl1
ChIP-seq and DNase-seq suggests that
(1) the Ascl1 binding profile remains con-
stant at the two stages analyzed, (2) a
large fraction of Ascl1 BEs occurs in re-
gions of open chromatin in proliferating
cells, with a subset falling within closed
chromatin, and (3) binding of Ascl1 to
closed chromatin precedes the appear-
ance of new DHSs during differentiation.Visualization of aligned Ascl1 ChIP-seq and DNase-seq data
suggests that many differentiation-induced DHSs overlap with
Ascl1 BEs (Figure 6A), as exemplified by those in the vicinity of
genes activated during differentiation such as NeuroD4,
Ap3b2, Mcf2l, and Nrxn3 (Figure 6B). Validation of changes in
chromatin compaction at the selected Ascl1 binding sites was
performed by FAIRE-PCR using chromatin extracted from NS5
cells expressing full-length Ascl1 under the regulation of a doxy-
cycline inducible promoter, before and after Ascl1 induction (Fig-
ure 6C). Although not all DHSs that arise de novo during, March 10, 2015 ª2015 The Authors 1551
Figure 6. Ascl1 Binds Closed Chromatin
and Promotes Chromatin Accessibility
(A) Visual representation of ChIP-seq and DNase-
seq enrichment profiles in the vicinity of various
Ascl1 targets. Examples are shown of differentia-
tion-induced and constant DHSs localized at
Ascl1 binding sites (green and red arrows,
respectively) and DHSs with no apparent associ-
ation with Ascl1 binding (blue arrows).
(B) Induction of expression of genes upon Ascl1-
induced differentiation as quantified by real-time
PCR. Data are represented as mean ± SD.
(C) FAIRE-PCR validation of differentiation-
induced DHSs at Ascl1 binding sites (green arrows
in A). Bars show quantification of genomic DNA
obtained from proliferating and differentiating NS
cells (before and 24 hr after induction, respec-
tively). Data are represented as mean ± SD.
(D) DNase-seq signal profile at genome-wide
Ascl1 BEs at t = 30 min (top left) or restricted to
BEs falling within differentiation-induced DHSs
(top right). Profile determined as the median read
count of DNase-seq reads mapped to the 4-kb
regions centered at the peak summits in prolifer-
ating (blue) and differentiating cells (red). (Bottom)
Corresponding fold change for the median pro-
files.
(E) Ascl1 BEs located at differentiation-induced
DHSs are significantly associated with clusters of
activated genes (left) and not with clusters of
repressed genes (right). Red bars, total number of
Ascl1 BEs annotated to each set of genes; box-
plots, distribution of Ascl1 BEs associations with
1,000 random sets of genes. Test data repre-
sented as box with median of test and first and
third quartiles; whiskers, ±1.5 3 IQR. See also
Figure S6.
(F) In vivo binding of Ascl1 to the NeuroD4 regu-
latory region assessed by ChIP-PCR using
chromatin extracted from mouse ventral telen-
cephalon. Data are represented as mean ± SD.
(G) Chromatin structure analysis by FAIRE-PCR of
NeuroD4 and Dll1 regulatory regions bound by
Ascl1, in mouse ventral telencephalon. Data are
represented as mean ± SD.differentiation are associated with an Ascl1 BE, as not all Ascl1
BEs overlap with changes detected by DNase-seq, the vast ma-
jority of Ascl1 BEs fall within DHSs in differentiating cells (91.05%
or 91.27% with p < 1018, at t = 30 min or t = 18 hr, respectively;
Figure 5F).
To investigate the correlation between Ascl1 binding and
changes in chromatin compaction on a large scale, we quantified
the DNase-seq signal from both time points centered on Ascl1
peak summits. Confirming previous observations, the overall
DNase-seq profile at Ascl1 peak summits is consistent with1552 Cell Reports 10, 1544–1556, March 10, 2015 ª2015 The Authorsmany BEs occurring in regions of already
open chromatin at t = 30 min (Figure 6D).
Nevertheless, a significant increase is
observed when comparing profiles
before and after differentiation (2.33 in-
crease of median read count) at Ascl1peak summits genome-wide (Figure 6D). This increase is ampli-
fied when focusing our analysis on Ascl1 peaks that fall within
differentiation-induced DHSs (4.37 increase of median read
count; Figure 6D). Ascl1 BEs co-localizing with differentiation-
induced DHSs are strongly associated with gene activation
and not with gene repression (p < 6.83 1032; Figure 6E), target-
ing a total number of 98 genes during differentiation. Overall, the
integration of Ascl1 location analysis, DNase-seq results, and
expression profiling demonstrate Ascl1 promotes genome-
wide changes in chromatin compaction at its target sites during
neuronal differentiation and the appearance of new DHSs asso-
ciated with activation of gene expression.
Our results are in agreement with the observation that Ascl1
can bind to nucleosomal DNAwhen overexpressed in fibroblasts
(Wapinski et al., 2013). To verify that Ascl1 can bind to closed
chromatin in a physiological context, we focused on the Ascl1-
bound regulatory region identified immediately downstream the
NeuroD4 promoter (BS2 in Figure 6A), a target gene of Ascl1 in
our cellular system that is not expressed in ventral telencephalon.
We reasoned that binding to closed chromatin to NeuroD4 may
still occur in this embryonic brain region at the neurogenic period,
even in the absence of gene expression. Indeed, we detected
strong binding of Ascl1, as compared with a negative control re-
gion within the NeuroD4 locus by ChIP-PCR in chromatin ex-
tracted from mouse ventral telencephalon (Figure 6F). However,
in contrast to our previous findings with differentiating NS cells in
culture, a lack of enrichment for non-nucleosomal DNA assessed
by FAIRE-PCR shows this Ascl1 target site is found within closed
chromatin in ventral telencephalon (Figure 6G, compare with
Ascl1 site in Dll1). Thus, our results with the NeuroD4 regulatory
region demonstrate that endogenous Ascl1 can bind to closed
chromatin in an in vivo context.
Finally, we wished to analyze the accessibility of chromatin at
Ascl1 target sites in the absence of Ascl1 expression. For this,
we used chromatin extracted from ventral telencephalon of
Ascl1-null embryos and probed Ascl1-bound regions associated
with previously validated Ascl1 target genes (Dll1, Fbxw7, and
Stk33) in this embryonic structure (Castro et al., 2006). Ascl1
null embryos show a very significant reduction of FAIRE-PCR
signal relative to WT chromatin at all tested Ascl1 binding sites,
as compared with pairwise control regions, which is consistent
with the results above and in support of a role for Ascl1 in regu-
lating chromatin compaction in vivo (Figure S6).
DISCUSSION
In spite of its pivotal role during neurogenesis, little is known on
how Ascl1 functions to regulate gene expression. Here we inves-
tigated the reciprocal interactions between Ascl1 and the chro-
matin landscape when promoting the neuronal differentiation
of NS cells in culture. We found that Ascl1 can bind to and pro-
mote the opening of closed chromatin regions in its native
context. Below we discuss our findings and their implications
to the mechanisms that govern the temporal progression of the
Ascl1 transcriptional program.
Our work resulted in a fine-grained characterization of a dif-
ferentiation program driven by Ascl1. In spite of displaying a
wide range of biological roles, Ascl1 target genes are remark-
ably enriched in two categories. The first consists of genes en-
coding transcriptional regulators, an observation consistent
with the master regulator function of Ascl1 in this develop-
mental process. Importantly, the activation of some TFs may
define feedback loops that modulate Ascl1 activity. This is the
case of Id1, an inhibitor of bHLH activity that functions by
sequestering E-proteins (Ruzinova and Benezra, 2003), and
Cbfa2t2/MTGR1, a zinc-finger protein that has been shown to
function as a co-repressor of proneural proteins, including
Ascl1 (Aaker et al., 2010). Other examples, suggesting positiveCellfeedback mechanisms, are TFs previously linked to a relief of
Notch inhibition by counteracting the activity of Hes1 (Hes6),
repressing Notch1 (Prox1), or by as yet unknown mechanisms
(MyT1) (Bellefroid et al., 1996; Gratton et al., 2003; Kaltezioti
et al., 2010). These regulatory events define a less
well-understood role of Ascl1 in modulating Notch signaling
cell autonomously, of putative importance to the progression
of differentiation. The second most prominent group of Ascl1
target genes encodes cytoskeleton-related proteins. The
abundance of this group of genes is likely to result from its
recognized role in many cellular functions, from signal trans-
duction (where it may serve as a scaffold for components of
signaling pathways) to cell shape change and locomotion,
activities that are essential to the neurogenic differentiation pro-
gram (Forgacs et al., 2004).
It was recently shown that Ascl1 promotes sequentially the
proliferation and differentiation along the neuronal lineage, with
the concomitant activation of distinct target genes (Castro
et al., 2011). Our study focused on the transcriptional program
activated by Ascl1 when promoting neuronal differentiation.
Comparing the identity and molecular determinants for target
gene specificity associated with both cellular functions will likely
require the characterization of Ascl1 binding profile in an oscilla-
tory versus sustained mode of expression. Nevertheless, the
observation that overexpressed Ascl1 can readily access the
full complement of its differentiation sites at the onset of differen-
tiation suggests these may already be accessible to this TF in
proliferating cells, an important observation in the context of
the dynamics of Ascl1 function along the neuronal lineage.
It was previously shown that overexpressed Ascl1 can bind to
closed chromatin in fibroblasts (as assessed by FAIRE-PCR),
defining it as a pioneer TF (Wapinski et al., 2013), results that
the present study validates for the first time in a neural context.
Moreover, our analysis of binding of Ascl1 to the NeuroD4 locus
in ventral telencephalic progenitors that do not express this gene
allowed for the dissociation between binding and opening of
chromatin, revealing binding of endogenous Ascl1 to closed
chromatin in vivo. Altogether, our study supports the idea that
Ascl1 displays its pioneer activity when regulating gene expres-
sion in its native context.
Our analysis of chromatin states suggests that most Ascl1
binding in our differentiation model occurs within enhancer re-
gions that are already active in proliferating NS cells as shown
by their enrichment for both H3K4me1 and H3K27ac. This
may be due to the fact that many genes upregulated by Ascl1
during differentiation are already expressed in proliferating NS
cells. Alternatively, it may reflect the trivalent mark (H3K4me1,
H3K27ac, and H3K9m3) identified at Ascl1 binding sites in
various cell types permissive to Ascl1-mediated reprogramming
(Wapinski et al., 2013). Most importantly, Ascl1 promotes
DNase I accessibility to regions of closed chromatin at a smaller
but significant number of its target sites associatedwith the acti-
vation of a differentiation-specific component of its transcrip-
tional program. Our results cast light into a previously unknown
function of Ascl1 and establish the first link between the chro-
matin landscape at Ascl1-bound regulatory regions and the
temporal pattern of the Ascl1 program along the neuronal line-
age. Moreover, they suggest that the hierarchical modelReports 10, 1544–1556, March 10, 2015 ª2015 The Authors 1553
recently proposed for the reprograming paradigm (Wapinski
et al., 2013) may also be representative of the neurogenesis pro-
cess and that opening of chromatin regions at Ascl1 target sites
may be important to allow subsequent binding of other TFs in
differentiating cells. Finally, it is tempting to speculate that the
broad effect of Ascl1 in promoting chromatin accessibility
described in this study will be important for the reprogramming
capacity of this TF upon its ectopic expression in various cell
types.
EXPERIMENTAL PROCEDURES
Plasmids and Virus Production
Ascl1-ERT2 encodes full-length mouse Ascl1 in frame with the modified ligand
binding domain of the human estrogen receptor (ERT2) and an N-terminal
Flag/HA tag sequence. For virus production, Ascl1-ERT2 was subcloned
into pMX-IRES-GFP or pBABE-IRES-GFP-puro. Replication-incompetent ret-
roviruses were produced from HEK293T cells transiently transfected with
retroviral, viral envelope-, and VSVG-pseudotyping plasmids. Retroviral parti-
cles were concentrated from supernatant by ultracentrifugation at 90,000 g for
90 min. Viral titers were typically 105–106 infectious particles/ml.
Culture and Infection of NS5 Cells
NS5 cells were cultured as previously described (Conti et al., 2005) using lam-
inin as media supplement (20 mg/ml). NS5 Ascl1-ERT2 cells were generated
upon infection with pBABE-Ascl1-ERT2-IRES-GFP-puro, followed by selec-
tion in complete medium containing 1-mg/ml puromycin (Calbiochem). For dif-
ferentiation, NS5 Ascl1-ERT2 cells were plated at 28,000 per cm2 of density
and induced with 50-nM 4-Hydroxytamoxifen, while reducing EGF concentra-
tion to 5 ng/ml.
Quantification of Ascl1 Protein Levels
All experiments were carried out upon approval and following the guidelines of
the ethics committee of Instituto Gulbenkian de Cie^ncia.
Quantification of Ascl1 (endogenous + Ascl1-ERT2) done by parallel immu-
nostaining with anti-Ascl1 antibody in acutely cultured primary ventral telen-
cephalon progenitors from E14.5 mouse embryos and NS5 Ascl1-ERT2 cells
(three replicates each). A total of 939 and 751 cells for embryonic and NS5 pro-
genitors, respectively, was imaged with identical exposure and images thresh-
olded and normalized—mean fluorescence per cell x (mean fluorescence of all
cells in picture/mean fluorescence of all cells per sample)—to define positive
cells. Fluorescence intensity was measured with ImageJ.
Expression Analysis of NS5 Ascl1-ERT2 Cells
Extraction of mRNA and cDNA synthesis performed as previously described
(Castro et al., 2011). Quantitative real-time PCR (qRT-PCR) was performed
according to the manufacturer using SYBR Green super-mix (Quanta
BioSciences) on an ABI7500 machine (Applied Biosystems). For microarray
analysis, quality of total RNA from biological triplicates was assessed using
Agilent Bioanalyser, and samples were processed according to the Illumina
Whole-genome Gene Expression Direct Hybridization Assay Guide, using Illu-
mina TotalPrep-96 RNA Amplification kit (Life Technologies). Quality control
was performed on labeled cRNA, and 750 ng of labeled cRNA was hybridized
toMouse Ref-8v2 arrays and scanned by BeedStudio v.3.1.3 (quantile normal-
ization with background correction). Normalization among arrays and signifi-
cant analysis were performed using GeneSpring X (Agilent). Further details
of data processing, including gene clustering, are described in Supplemental
Information.
ChIP-seq
For Ascl1 ChIP-seq, NS5 Ascl1-ERT2 cells were fixed sequentially with 2 mM
di(N-succimidyl) glutarate and 1% formaldehyde in PBS and then lysed, son-
icated, and immunoprecipitated with anti-HA antibody, as previously
described (Castro et al., 2011). DNA libraries were prepared from 10 ng of
immunoprecipitated DNA according to the standard Illumina ChIP-seq proto-1554 Cell Reports 10, 1544–1556, March 10, 2015 ª2015 The Authorcol and sequenced with Illumina GAIIx. Raw reads were mapped to the mouse
genome (NCBI37/mm9) with Bowtie 0.12.7 (Langmead et al., 2009). Uniquely
mapped reads data (11.5 million for both Ascl1 ChIP and input chromatin
samples) were then subsampled before peak calling with MACS 1.4.1 (Zhang
et al., 2008). For histone marks ChIP-seq, Ascl1-ERT2 cells were fixed in 1%
formaldehyde in PBS, prepared as described above and immunoprecipitated
with anti-H3K27ac and anti-H3K4me1 antibodies. Libraries were sequenced
with Illumina HiSeq 2000. Raw reads were mapped as above (25 million
uniquely mapped reads for all samples) and data processed with MACS
2.1.0. For chromatin state characterization, we used a Hidden Markov
modeling of chromatin enrichment software—ChromHMM (Ernst and Kellis,
2012). Further details of data processing are described in Supplemental
Information.
FAIRE-PCR
Chromatin preparation was done with a single fixation with 1% formaldehyde,
from NS5 Ascl1-ERT2 cells, or when indicated with NS5 cells infected with a
doxycycline inducible lentivirus expressing WT Ascl1 (Wapinski et al., 2013).
Three rounds of phenol/chloroform extraction were followed by isopropanol
precipitation of the DNA. Quantification of genomic regions was done using
a standard curve generated with decross-linked input chromatin by qRT-
PCR as above.
DNase-seq
DNase-seq samples from differentiating NS5 Ascl1-ERT2 cells or proliferating
NS5 cells were prepared as previously described (Song et al., 2011). Libraries
were generated as previously described (Boyle et al., 2008; Song and
Crawford, 2010) with a slight modification to the linkers to increase ligation ef-
ficiency (Song et al., 2011) and then sequenced with Illumina GAIIx. Mapping
was done as for ChIP-seq, resulting in 165.9 and 168.7millions of unique reads
for proliferating and differentiating conditions, respectively. Genomic location
of DHSs was identified with MACS version 1.4.1, following a protocol
described in Supplemental Information.
For oligonucleotides used in this study, see also Table S10.
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